Delaware
|
|
001-35867
|
|
33-0903395
|
(State or other jurisdiction
|
|
(Commission File Number)
|
|
(IRS Employer Identification No.)
|
of incorporation)
|
|
|
|
|
2505 Meridian Parkway, Suite 100
Durham, NC
|
|
27713
|
(Address of principal executive offices)
|
|
(Zip Code)
|
|
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
Common Stock, par value $0.001 per share
|
CMRX
|
The Nasdaq Global Market
|
Item 5.02
|
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
|
|
Chimerix, Inc.
|
||
|
|
|
|
Dated: April 10, 2020
|
|
|
|
|
|
By:
|
/s/ Michael T. Andriole
|
|
|
|
Michael T. Andriole
|
|
|
|
Chief Business and Financial Officer
|